Simplify Logo

Full-Time

Research Associate II

Confirmed live in the last 24 hours

Cytokinetics

Cytokinetics

201-500 employees

Develops drugs for muscle function improvement

Biotechnology
Healthcare

Compensation Overview

$94k - $114kAnnually

Junior, Mid

San Bruno, CA, USA

Category
Lab & Research
Life Sciences
Required Skills
Communications
Requirements
  • BS/MS in Biology, Physiology, Pharmacology, or a related field with 2+ years of relevant research experience
  • Proficiency in basic rodent handling and dosing techniques is required
  • Basic data management skills and the ability to present data clearly and effectively
  • Excellent oral and written communication skills are essential
Responsibilities
  • Conduct and manage in vivo experiments assessing the efficacy of small molecule compounds related to cardiac diseases
  • Oversee animal colony cohorts for in vivo studies, ensuring adherence to ethical guidelines and protocols
  • Measure biomarkers of disease progression and compound efficacy
  • Collaborate closely with team members to identify, characterize, and progress compounds through preclinical research stages
  • Document experimental results, manage data, prepare and present summary presentations to project teams

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

Company Stage

IPO

Total Funding

$1.2B

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

21%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful Phase III trial results for aficamten in treating obstructive hypertrophic cardiomyopathy (HCM) highlight the company's potential for market leadership in this area.
  • The $575M funding from Royalty Pharma ensures strong financial support for the commercial launch of aficamten and further R&D activities.
  • Recent investments and stock offerings indicate strong investor confidence and provide additional capital for growth and development.

What critics are saying

  • The late-stage biopharmaceutical market is highly competitive, with significant pressure to bring drugs to market quickly and efficiently.
  • Dependence on the success of clinical trials and regulatory approvals poses inherent risks, as any setbacks could delay commercialization and revenue generation.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle function improvement for cardiovascular and neuromuscular diseases, a niche area with high unmet medical needs.
  • The company has a robust pipeline of small molecule muscle activators and inhibitors, setting it apart from competitors with more generalized drug portfolios.
  • Strategic funding collaborations, such as the $575M deal with Royalty Pharma, provide significant financial backing for their R&D and commercialization efforts.